Literature DB >> 3598893

A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine.

N M Cintrón, Y M Chen.   

Abstract

A sensitive and reliable procedure for the quantitation of low picogram levels of scopolamine in plasma and urine is described. The method consists of two steps, a preparative extraction step using C18 columns (Sep-Pak), followed by an analytical quantitation step involving a muscarinic radioreceptor assay. The extraction efficiency of the C18 columns was 85-95% for both plasma and urine over a wide concentration range. When [3H]methyl scopolamine is used as a tracer, the assay can detect picogram concentrations (greater than 25 pg) of scopolamine (base) in plasma and urine. The applicability of the procedure for therapeutic drug monitoring of scopolamine was demonstrated by using the method to determine plasma levels in humans after transdermal administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598893     DOI: 10.1002/jps.2600760413

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects.

Authors:  S Ahmed; A P Sileno; J C deMeireles; R Dua; H K Pimplaskar; W J Xia; J Marinaro; E Langenback; F J Matos; L Putcha; V D Romeo; C R Behl
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

Authors:  Zohar Nachum; Avi Shupak; Carlos R Gordon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.

Authors:  L Putcha; N M Cintrón; J Tsui; J M Vanderploeg; W G Kramer
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

Review 4.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.